Catalent Belgium SA – FDA 483, Oct 26, 2021
Catalent Belgium S.A. in Brussels was inspected and cited for significant deficiencies across its drug product manufacturing operations. The inspection revealed failures in thoroughly investigating discrepancies like HEPA filter failures and environmental monitoring excursions, as well as inadequate process and cleaning validations for sterile products. Additionally, issues with equipment maintenance, facility design, and adherence to standard operating procedures were noted, indicating a broad lack of control over critical manufacturing processes.
ID · 5f428877-75e7-4d0c-a321-d784b42dae0b
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.